1
|
Wharton's Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View. Pharmaceutics 2021; 13:pharmaceutics13091336. [PMID: 34575412 PMCID: PMC8471243 DOI: 10.3390/pharmaceutics13091336] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 08/18/2021] [Accepted: 08/23/2021] [Indexed: 12/18/2022] Open
Abstract
Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particularly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton's jelly MSC and derived EV in post-MI management.
Collapse
|
2
|
Directional Topography Influences Adipose Mesenchymal Stromal Cell Plasticity: Prospects for Tissue Engineering and Fibrosis. Stem Cells Int 2019; 2019:5387850. [PMID: 31191675 PMCID: PMC6525798 DOI: 10.1155/2019/5387850] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2018] [Revised: 12/24/2018] [Accepted: 02/11/2019] [Indexed: 01/17/2023] Open
Abstract
Introduction Progenitor cells cultured on biomaterials with optimal physical-topographical properties respond with alignment and differentiation. Stromal cells from connective tissue can adversely differentiate to profibrotic myofibroblasts or favorably to smooth muscle cells (SMC). We hypothesized that myogenic differentiation of adipose tissue-derived stromal cells (ASC) depends on gradient directional topographic features. Methods Polydimethylsiloxane (PDMS) samples with nanometer and micrometer directional topography gradients (wavelength (w) = 464-10, 990 nm; amplitude (a) = 49-3, 425 nm) were fabricated. ASC were cultured on patterned PDMS and stimulated with TGF-β1 to induce myogenic differentiation. Cellular alignment and adhesion were assessed by immunofluorescence microscopy after 24 h. After seven days, myogenic differentiation was examined by immunofluorescence microscopy, gene expression, and immunoblotting. Results Cell alignment occurred on topographies larger than w = 1758 nm/a = 630 nm. The number and total area of focal adhesions per cell were reduced on topographies from w = 562 nm/a = 96 nm to w = 3919 nm/a = 1430 nm. Focal adhesion alignment was increased on topographies larger than w = 731 nm/a = 146 nm. Less myogenic differentiation of ASC occurred on topographies smaller than w = 784 nm/a = 209 nm. Conclusion ASC adherence, alignment, and differentiation are directed by topographical cues. Our evidence highlights a minimal topographic environment required to facilitate the development of aligned and differentiated cell layers from ASC. These data suggest that nanotopography may be a novel tool for inhibiting fibrosis.
Collapse
|
3
|
Ganeshan V, Skladnev NV, Kim JY, Mitrofanis J, Stone J, Johnstone DM. Pre-conditioning with Remote Photobiomodulation Modulates the Brain Transcriptome and Protects Against MPTP Insult in Mice. Neuroscience 2019; 400:85-97. [PMID: 30625333 DOI: 10.1016/j.neuroscience.2018.12.050] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Revised: 12/18/2018] [Accepted: 12/30/2018] [Indexed: 12/14/2022]
Abstract
Transcranial photobiomodulation (PBM), which involves the application of low-intensity red to near-infrared light (600-1100 nm) to the head, provides neuroprotection in animal models of various neurodegenerative diseases. However, the absorption of light energy by the human scalp and skull may limit the utility of transcranial PBM in clinical contexts. We have previously shown that targeting light at peripheral tissues (i.e. "remote PBM") also provides protection of the brain in an MPTP mouse model of Parkinson's disease, suggesting remote PBM might be a viable alternative strategy for overcoming penetration issues associated with transcranial PBM. This present study aimed to determine an effective pre-conditioning regimen of remote PBM for inducing neuroprotection and elucidate the molecular mechanisms by which remote PBM enhances the resilience of brain tissue. Balb/c mice were irradiated with 670-nm light (4 J/cm2 per day) targeting dorsum and hindlimbs for 2, 5 or 10 days, followed by injection of the parkinsonian neurotoxin MPTP (50 mg/kg) over two consecutive days. Despite no direct irradiation of the head, 10 days of pre-conditioning with remote PBM significantly attenuated MPTP-induced loss of midbrain tyrosine hydroxylase-positive dopaminergic cells and mitigated the increase in FOS-positive neurons in the caudate-putamen complex. Interrogation of the midbrain transcriptome by RNA microarray and pathway enrichment analysis suggested upregulation of cell signaling and migration (including CXCR4+ stem cell and adipocytokine signaling), oxidative stress response pathways and modulation of the blood-brain barrier following remote PBM. These findings establish remote PBM preconditioning as a viable neuroprotective intervention and provide insights into the mechanisms underlying this phenomenon.
Collapse
Affiliation(s)
- Varshika Ganeshan
- Bosch Institute, University of Sydney, NSW 2006, Australia; Discipline of Physiology, University of Sydney, NSW 2006, Australia
| | - Nicholas V Skladnev
- Bosch Institute, University of Sydney, NSW 2006, Australia; Discipline of Physiology, University of Sydney, NSW 2006, Australia
| | - Ji Yeon Kim
- Bosch Institute, University of Sydney, NSW 2006, Australia; Discipline of Physiology, University of Sydney, NSW 2006, Australia; School of Medicine, University of Queensland Centre for Clinical Research, QLD 4029, Australia
| | - John Mitrofanis
- Bosch Institute, University of Sydney, NSW 2006, Australia; Discipline of Anatomy & Histology, University of Sydney, NSW 2006, Australia
| | - Jonathan Stone
- Bosch Institute, University of Sydney, NSW 2006, Australia; Discipline of Physiology, University of Sydney, NSW 2006, Australia
| | - Daniel M Johnstone
- Bosch Institute, University of Sydney, NSW 2006, Australia; Discipline of Physiology, University of Sydney, NSW 2006, Australia.
| |
Collapse
|
4
|
Guerra-Rebollo M, Nogueira de Moraes C, Alcoholado C, Soler-Botija C, Sanchez-Cid L, Vila OF, Meca-Cortés O, Ramos-Romero S, Rubio N, Becerra J, Blanco J, Garrido C. Glioblastoma Bystander Cell Therapy: Improvements in Treatment and Insights into the Therapy Mechanisms. MOLECULAR THERAPY-ONCOLYTICS 2018; 11:39-51. [PMID: 30364660 PMCID: PMC6197388 DOI: 10.1016/j.omto.2018.09.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Accepted: 09/12/2018] [Indexed: 01/14/2023]
Abstract
A preclinical model of glioblastoma (GB) bystander cell therapy using human adipose mesenchymal stromal cells (hAMSCs) is used to address the issues of cell availability, quality, and feasibility of tumor cure. We show that a fast proliferating variety of hAMSCs expressing thymidine kinase (TK) has therapeutic capacity equivalent to that of TK-expressing hAMSCs and can be used in a multiple-inoculation procedure to reduce GB tumors to a chronically inhibited state. We also show that up to 25% of unmodified hAMSCs can be tolerated in the therapeutic procedure without reducing efficacy. Moreover, mimicking a clinical situation, tumor debulking previous to cell therapy inhibits GB tumor growth. To understand these striking results at a cellular level, we used a bioluminescence imaging strategy and showed that tumor-implanted therapeutic cells do not proliferate, are unaffected by GCV, and spontaneously decrease to a stable level. Moreover, using the CLARITY procedure for tridimensional visualization of fluorescent cells in transparent brains, we find therapeutic cells forming vascular-like structures that often associate with tumor cells. In vitro experiments show that therapeutic cells exposed to GCV produce cytotoxic extracellular vesicles and suggest that a similar mechanism may be responsible for the in vivo therapeutic effectiveness of TK-expressing hAMSCs.
Collapse
Affiliation(s)
- Marta Guerra-Rebollo
- Cell Therapy Group, Catalonian Institute for Advanced Chemistry (IQAC-CSIC), 08034 Barcelona, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28040 Madrid, Spain
| | - Carolina Nogueira de Moraes
- Department of Animal Reproduction and Veterinary Radiology, College of Veterinary Medicine and Animal Science, São Paulo State University, UNESP, 18618-681 Botucatu, Brazil
| | - Cristina Alcoholado
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28040 Madrid, Spain
- Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, University of Málaga, Biomedical Research Institute of Málaga (IBIMA), 29071 Málaga, Spain
| | - Carolina Soler-Botija
- ICREC Research Program, Health Science Research Institute Germans Trias i Pujol, 08916 Badalona, Spain
- CIBER Cardiovascular, Carlos III Health Institute, 28029 Madrid, Spain
| | - Lourdes Sanchez-Cid
- Cell Therapy Group, Catalonian Institute for Advanced Chemistry (IQAC-CSIC), 08034 Barcelona, Spain
| | - Olaia F. Vila
- Cell Therapy Group, Catalonian Institute for Advanced Chemistry (IQAC-CSIC), 08034 Barcelona, Spain
- Department of Biomedical Engineering, Columbia University, New York, NY 10032, USA
| | - Oscar Meca-Cortés
- Cell Therapy Group, Catalonian Institute for Advanced Chemistry (IQAC-CSIC), 08034 Barcelona, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28040 Madrid, Spain
| | - Sara Ramos-Romero
- Cell Therapy Group, Catalonian Institute for Advanced Chemistry (IQAC-CSIC), 08034 Barcelona, Spain
- Department of Cell Biology, Physiology & Immunology, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain
| | - Nuria Rubio
- Cell Therapy Group, Catalonian Institute for Advanced Chemistry (IQAC-CSIC), 08034 Barcelona, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28040 Madrid, Spain
| | - José Becerra
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28040 Madrid, Spain
- Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, University of Málaga, Biomedical Research Institute of Málaga (IBIMA), 29071 Málaga, Spain
- Laboratory of Bioengineering and Tissue Regeneration (LABRET), Andalusian Center for Nanomedicine and Biotechnology-BIONAND, 29590 Málaga, Spain
| | - Jeronimo Blanco
- Cell Therapy Group, Catalonian Institute for Advanced Chemistry (IQAC-CSIC), 08034 Barcelona, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28040 Madrid, Spain
| | - Cristina Garrido
- Cell Therapy Group, Catalonian Institute for Advanced Chemistry (IQAC-CSIC), 08034 Barcelona, Spain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28040 Madrid, Spain
- Corresponding author: Cristina Garrido, Cell Therapy Group, Catalonian Institute for Advanced Chemistry (IQAC-CSIC), Jordi Girona Street, 18-26, 08034 Barcelona, Spain.
| |
Collapse
|
5
|
Zhang L, Wang XY, Zhou PJ, He Z, Yan HZ, Xu DD, Wang Y, Fu WY, Ruan BB, Wang S, Chen HX, Liu QY, Zhang YX, Liu Z, Wang YF. Use of immune modulation by human adipose-derived mesenchymal stem cells to treat experimental arthritis in mice. Am J Transl Res 2017; 9:2595-2607. [PMID: 28560007 PMCID: PMC5446539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2016] [Accepted: 04/26/2017] [Indexed: 06/07/2023]
Abstract
Rheumatoid arthritis is a chronic and systemic autoimmune disease characterized by inflammatory cell infiltration and joint erosion. Human adipose-derived mesenchymal stem cells (hASCs) have shown the capacity of suppressing effector T cell activation and inflammatory cytokine expression. We investigated whether hASCs play a therapeutic role in collagen-induced arthritis (CIA) by administering a single dose of hASCs in mice with established CIA. In vivo, a beneficial effect was observed following hASC infusion as shown by a marked decrease in the severity of arthritis. Human ASCs were detectable in the joints, and reduced levels of pro-inflammatory cytokines and increased levels of anti-inflammatory cytokines were observed in the sera of the hASC-treated mice. Furthermore, hASC treatment induced the expansion of regulatory T cells (Tregs) both in the peripheral blood and in the spleen tissues. In vitro, hASCs downregulated the production of proinflammatory cytokines TNF-α, IL-1β, and IL-6 in mouse macrophages stimulated with lipopolysaccharide and inhibited the proliferation of human primary T cells in response to mitogens. Thus hASCs represent a novel and effective therapeutic strategy for RA.
Collapse
Affiliation(s)
- Li Zhang
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
- Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityGuangzhou 510623, Guangdong, China
| | - Xiao-Yan Wang
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Peng-Jun Zhou
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Zhe He
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Hai-Zhao Yan
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Dan-Dan Xu
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Ying Wang
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Wu-Yu Fu
- Department of Pathogen Biology and Immunology, School of Basic Study, Guangdong Pharmaceutical UniversityGuangzhou 510632, China
| | - Bi-Bo Ruan
- Department of Pathogen Biology and Immunology, School of Basic Study, Guangdong Pharmaceutical UniversityGuangzhou 510632, China
| | - Sheng Wang
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Hai-Xuan Chen
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Qiu-Ying Liu
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Yu-Xia Zhang
- Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityGuangzhou 510623, Guangdong, China
| | - Zhong Liu
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| | - Yi-Fei Wang
- Key Laboratory of Bioengineering Medicine of Guangdong Province, College of Life Science and Technology, Jinan UniversityGuangzhou 510632, China
| |
Collapse
|
6
|
Osteogenic differentiation of adipose tissue-derived mesenchymal stem cells cultured on a scaffold made of silk fibroin and cord blood platelet gel. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2016; 14:206-11. [PMID: 27177408 DOI: 10.2450/2016.0209-15] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Accepted: 12/01/2015] [Indexed: 01/22/2023]
|
7
|
Roura S, Gálvez-Montón C, Bayes-Genis A. Fibrin, the preferred scaffold for cell transplantation after myocardial infarction? An old molecule with a new life. J Tissue Eng Regen Med 2016; 11:2304-2313. [PMID: 27061269 DOI: 10.1002/term.2129] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Revised: 11/13/2015] [Accepted: 12/10/2015] [Indexed: 12/12/2022]
Abstract
Fibrin is a topical haemostat, sealant and tissue glue, which consists of concentrated fibrinogen and thrombin. It has broad medical and research uses. Recently, several studies have shown that engineered patches comprising mixtures of biological or synthetic materials and progenitor cells showed therapeutic promise for regenerating damaged tissues. In that context, fibrin maintains cell adherence at the site of injury, where cells are required for tissue repair, and offers a nurturing environment that protects implanted cells without interfering with their expected benefit. Here we review the past, present and future uses of fibrin, with a focus on its use as a scaffold material for cardiac repair. Fibrin patches filled with regenerative cells can be placed over the scarring myocardium; this methodology avoids many of the drawbacks of conventional cell-infusion systems. Advantages of using fibrin also include extraction from the patient's blood, an easy readjustment and implantation procedure, increase in viability and early proliferation of delivered cells, and benefits even with the patch alone. In line with this, we discuss the numerous preclinical studies that have used fibrin-cell patches, the practical issues inherent in their generation, and the necessary process of scaling-up from animal models to patients. In the light of the data presented, fibrin stands out as a valuable biomaterial for delivering cells to damaged tissue and for promoting beneficial effects. However, before the fibrin scaffold can be translated from bench to bedside, many issues must be explored further, including suboptimal survival and limited migration of the implanted cells to underlying ischaemic myocardium. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Santiago Roura
- Heart Failure and Cardiac Regeneration (ICREC) Research Programme, Germans Trias i Pujol Health Science Research Institute, Badalona, Barcelona, Spain.,Center of Regenerative Medicine in Barcelona, Barcelona, Spain
| | - Carolina Gálvez-Montón
- Heart Failure and Cardiac Regeneration (ICREC) Research Programme, Germans Trias i Pujol Health Science Research Institute, Badalona, Barcelona, Spain
| | - Antoni Bayes-Genis
- Heart Failure and Cardiac Regeneration (ICREC) Research Programme, Germans Trias i Pujol Health Science Research Institute, Badalona, Barcelona, Spain.,Cardiology Service, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain.,Department of Medicine, Universitat Autònoma de Barcelona, Spain
| |
Collapse
|